Get the Stockscreener App
1.66
2.35%
-0.04
Aprea Therapeutics Inc stock is traded at $1.66, with a volume of 42,900.
It is down -2.35% in the last 24 hours and up +0.61% over the past month.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
See More
Previous Close:
$1.70
Open:
$1.75
24h Volume:
42,900
Relative Volume:
1.04
Market Cap:
$9.18M
Revenue:
-
Net Income/Loss:
$-14.29M
P/E Ratio:
-0.416
EPS:
-3.99
Net Cash Flow:
$-12.27M
1W Performance:
-12.17%
1M Performance:
+0.61%
6M Performance:
-57.54%
1Y Performance:
-55.14%
1-Day Range:
$1.65
$1.85
1-Week Range:
$1.65
$1.9335
52-Week Range:
$1.412
$5.01
Aprea Therapeutics Inc Stock (APRE) Company Profile
Name
Aprea Therapeutics Inc
Sector
Industry
Phone
215-948-4119
Address
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Compare APRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
1.66 | 9.40M | 0 | -14.29M | -12.27M | -3.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Jun-22-20 | Initiated | H.C. Wainwright | Neutral |
| Apr-21-20 | Initiated | Robert W. Baird | Outperform |
| Oct-28-19 | Initiated | JP Morgan | Neutral |
| Oct-28-19 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-28-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Aprea Therapeutics Inc Stock (APRE) Latest News
Quantitative breakdown of Aprea Therapeutics Inc. recent moveReliable Setup Screener with Low Risk - Newser
Key resistance and support levels for Aprea Therapeutics Inc.Proven Trading System with Consistent Gains - Newser
Has Aprea Therapeutics Inc. found a price floorAI Entry Timing Prediction for Swing Traders - Newser
What’s next for Aprea Therapeutics Inc. stock priceFree Triple Digit Return Stock Predictions - Newser
Is Aprea Therapeutics Inc. trending in predictive chart modelsTechnical Entry Plan with Risk Minimization - Newser
Published on: 2025-08-01 21:22:33 - Newser
Is Aprea Therapeutics Inc. forming a bottoming baseFundamental Forecast for Undervalued Stocks - Newser
What catalysts could drive Aprea Therapeutics Inc. stock higher in 2025Retirement Planning Data Feed That Work - jammulinksnews.com
Aprea Therapeutics Inc. stock momentum explained3-Day Market Movement Forecast Analysis - Newser
Trend analysis for Aprea Therapeutics Inc. this weekFree AI Forecast for Trending Stocks - Newser
Why Aprea Therapeutics Inc. stock attracts strong analyst attentionPrice Movement and Market Sentiment Analysis - Newser
Analyzing recovery setups for Aprea Therapeutics Inc. investorsTechnical Screener for High Growth Stocks - Newser
Is it too late to sell Aprea Therapeutics Inc.Technical Screener for High Growth Stocks - Newser
Real time social sentiment graph for Aprea Therapeutics Inc.Swing Candidate List with Trade Cues - Newser
Applying Wyckoff theory to Aprea Therapeutics Inc. stockTechnical Entry Plan with Risk Minimization - Newser
Is Aprea Therapeutics Inc. stock reversal real or fakePrice Action Summary and Entry Strategy Guide - Newser
Is Aprea Therapeutics Inc. Stock Overbought or Oversold RSI Indicator AnalysisFree Pattern Detection for Entry Confirmation - Newser
Is Aprea Therapeutics Inc. meeting your algorithmic filter criteriaBuy and Exit Strategy Based on Momentum - Newser
How Aprea Therapeutics Inc. stock performs during market volatilityStep-by-Step Trade Signal Implementation Guide Ready - metal.it
Is This a Bottoming Phase for Aprea Therapeutics Inc.Smart Trade Plans With Risk Protection Explained - metal.it
Aprea Therapeutics Inc. Recovery Linked to Earnings SurpriseTrade Scanner With Buy Zone Alerts Flagged - metal.it
Published on: 2025-07-29 23:07:30 - metal.it
How did APRE's Q4 2024 earnings surprise investors? - AInvest
Buy Signal for Aprea Therapeutics Inc. Stock Key Technical Indicators to WatchReal Time Trade Execution Alert Plan - Newser
How Resilient Is Aprea Therapeutics Inc. Stock During Economic DownturnsExpert-Backed High Yield Stock Watchlist - Newser
Published on: 2025-07-28 15:10:55 - metal.it
Does Aprea Therapeutics Inc. stock perform well during market downturnsBreakthrough profit margins - jammulinksnews.com
What are analysts’ price targets for Aprea Therapeutics Inc. in the next 12 monthsRecord-setting profit potential - jammulinksnews.com
What is Aprea Therapeutics Inc. company’s growth strategyTurn market volatility into profit opportunities - jammulinksnews.com
Why is Aprea Therapeutics Inc. stock attracting strong analyst attentionHigh-performance investment picks - jammulinksnews.com
What institutional investors are buying Aprea Therapeutics Inc. stockAchieve breakthrough performance in the market - jammulinksnews.com
What makes Aprea Therapeutics Inc. stock price move sharplyPhenomenal wealth increase - jammulinksnews.com
What are Aprea Therapeutics Inc. company’s key revenue driversDiscover the next big stock winners - jammulinksnews.com
Published on: 2025-07-28 05:37:59 - jammulinksnews.com
When is Aprea Therapeutics Inc. stock expected to show significant growthFree Investment Community - jammulinksnews.com
Aprea Therapeutics Inc Stock (APRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):